Literature DB >> 12376053

A cohort of children hospitalised with acute RSV bronchiolitis: impact on later respiratory disease.

Nele Sigurs1.   

Abstract

This paper reviews the results from a cohort study in which 47 children hospitalised with respiratory syncytial virus (RSV) bronchiolitis and their 93 controls, matched for age, sex and place of living, were prospectively followed-up at the mean ages of 1, 3 and 7.5. Asthma was significantly more common in the RSV bronchiolitis group at all times. Asthma during the year prior to follow-up at age 7.5 was seen in 23% of the RSV children and in 2% of the controls (P < 0.001). Allergic sensitisation was found in 41% of the RSV children and in 22% of the controls (P = 0.039). When comparing these results with findings from other studies it is obvious that the rate of asthma and other bronchial obstructive symptoms are increased after RSV bronchiolitis but the various results concerning allergic sensitisation are not conclusive. Prospective studies are needed with some kind of randomised intervention against RSV before the mechanisms behind the post-bronchiolitic symptoms and the possibly increased risk for IgE mediated allergy can be settled. Copyright 2002 Elsevier Science Ltd.

Entities:  

Mesh:

Year:  2002        PMID: 12376053     DOI: 10.1016/s1526-0542(02)00191-4

Source DB:  PubMed          Journal:  Paediatr Respir Rev        ISSN: 1526-0542            Impact factor:   2.726


  23 in total

1.  Cutting edge: CD49d+ neutrophils induce FcepsilonRI expression on lung dendritic cells in a mouse model of postviral asthma.

Authors:  Dorothy S Cheung; Sarah J Ehlenbach; Robert T Kitchens; Desiré A Riley; Larry L Thomas; Michael J Holtzman; Mitchell H Grayson
Journal:  J Immunol       Date:  2010-09-27       Impact factor: 5.422

2.  Respiratory virus-induced TLR7 activation controls IL-17-associated increased mucus via IL-23 regulation.

Authors:  Nicholas W Lukacs; Joost J Smit; Sumanta Mukherjee; Susan B Morris; Gabriel Nunez; Dennis M Lindell
Journal:  J Immunol       Date:  2010-07-12       Impact factor: 5.422

3.  Respiratory syncytial virus infection modifies and accelerates pulmonary disease via DC activation and migration.

Authors:  Sihyug Jang; Joost Smit; Lara E Kallal; Nicholas W Lukacs
Journal:  J Leukoc Biol       Date:  2013-01-04       Impact factor: 4.962

Review 4.  Vaccines for the Paramyxoviruses and Pneumoviruses: Successes, Candidates, and Hurdles.

Authors:  Charles J Russell; Eric A F Simões; Julia L Hurwitz
Journal:  Viral Immunol       Date:  2018-01-11       Impact factor: 2.257

5.  Respiratory virus-induced regulation of asthma-like responses in mice depends upon CD8 T cells and interferon-gamma production.

Authors:  Joost J Smit; Louis Boon; Nicholas W Lukacs
Journal:  Am J Pathol       Date:  2007-11-08       Impact factor: 4.307

6.  Cross-linking IgE augments human conventional dendritic cell production of CC chemokine ligand 28.

Authors:  Sadia Hayat Khan; Mitchell H Grayson
Journal:  J Allergy Clin Immunol       Date:  2009-12-04       Impact factor: 10.793

7.  Economic results of a palivizumab seasonal prophylaxis using a cohorting software and vial sharing.

Authors:  Elio Coletta; Salvatore Coppolino; Febronia Federico; Francesco Fulia
Journal:  Ital J Pediatr       Date:  2010-07-07       Impact factor: 2.638

Review 8.  Epidemiologic, experimental, and clinical links between respiratory syncytial virus infection and asthma.

Authors:  Shyam S Mohapatra; Sandhya Boyapalle
Journal:  Clin Microbiol Rev       Date:  2008-07       Impact factor: 26.132

Review 9.  Role of viruses in the development of atopic disease in pediatric patients.

Authors:  Dorothy S Cheung; Mitchell H Grayson
Journal:  Curr Allergy Asthma Rep       Date:  2012-12       Impact factor: 4.806

Review 10.  Understanding the mechanisms of viral induced asthma: new therapeutic directions.

Authors:  Nicole G Hansbro; Jay C Horvat; Peter A Wark; Philip M Hansbro
Journal:  Pharmacol Ther       Date:  2008-01-29       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.